Menlo therapeutics inc. (MNLO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
TOTAL REVENUES

1,750

-

-

-

308

-

-

-

-

-

-

-

-

EXPENSES
Cost of goods sold

271

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration and license revenue

-

-

-

-

-

0

0

10,143

497

-

909

449

-

Collaboration and license revenue

-

-

-

-

-

-

-

-

-

-

-

-

449

Operating expenses:
Research and development

15,953

16,834

12,622

13,457

10,848

15,076

10,667

16,226

11,020

10,547

8,008

5,460

4,992

Selling, general and administrative

25,415

-

-

-

5,344

-

-

-

-

-

-

-

-

TOTAL EXPENSES

41,639

-

-

-

16,192

-

-

-

-

-

-

-

-

General and administrative

-

-

4,804

3,759

-

3,364

3,035

3,090

2,697

1,706

1,236

1,214

1,012

Total operating expenses

-

-

17,426

17,216

-

18,440

13,702

19,316

13,717

12,253

9,244

6,674

6,004

OPERATING LOSS

-39,889

-25,716

-17,426

-17,216

-15,884

-18,440

-13,702

-9,173

-13,220

-9,478

-8,335

-6,225

-5,555

FINANCE INCOME

728

-

-

-

536

-

-

-

-

-

-

-

-

FINANCE EXPENSES

1,072

-

-

-

32

-

-

-

-

-

-

-

-

LOSS BEFORE INCOME TAX

-40,233

-

-

-

-15,380

-

-

-

-

-

-

-

-

INCOME TAX

-

-

-

-

-176

-

-

-

-

-

-

-

-

Interest income and other expense, net

-

-

571

739

-

846

855

826

563

-

163

-

-

Interest income and other expense, net

-

-

-

-

-

-

-

-

-

-

-

72

81

NET LOSS FOR THE PERIOD

-40,233

-25,167

-16,855

-16,477

-15,204

-17,594

-12,847

-8,347

-12,657

-9,277

-8,172

-6,153

-5,474

Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities

-

-

30

15

-

5

48

53

-151

-10

-19

8

-4

Comprehensive loss

-

-

-16,825

-16,462

-

-17,589

-12,799

-8,294

-12,808

-9,287

-8,191

-6,145

-5,478

LOSS PER SHARE BASIC AND DILUTED (in USD per share)

0.95

-2.17

-0.70

-0.69

0.47

-0.73

-0.56

-0.36

-0.72

-1.80

-1.60

-1.21

-1.08

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS (in shares)

42,510

15,216

23,955

23,893

32,209

23,241

22,977

22,872

17,583

5,152

5,116

5,092

5,071

Product sales
TOTAL REVENUES

1,750

-

-

-

-

-

-

-

-

-

-

-

-

Royalty revenues
TOTAL REVENUES

0

-

-

-

308

-

-

-

-

-

-

-

-